Facility

LIFELINE FIRST AID LLC

1 recall(s) on record — most severe on record: Class II.

Key facts

1recalls · worst Class II

—inspections in our data

—warning letters in our data

Recalls are listed for the parent company: openFDA recall records do not name a facility. How we attribute records

FDA Establishment Identifier (FEI)	3002714597
Establishment type	Repack or Relabel Medical Device; Develop Specifications But Do Not Manufacture At This Facility
Location	6710 SW McEwan Rd Lake Oswego, OR, US 97035
Registration status	Active · expires 2026
Parent company	LIFELINE FIRST AID LLC (owner-operator 9060173)
Brand names	TAPE011; TAPE001; Lifeline First Aid

Activity by year

Recalls (1)

Devices registered here (1)

Tape And Bandage, Adhesive
Product code KGX (opens in a new tab) · Class I · General Hospital · 21 CFR 880.5240

Recalls & enforcement

Class IITerminated2016-05-16
First aid kits or rescue kits are recalled because they contains the CPR Shield with One Way Valve and Barrier Filter (mask) and this mask is cleared only for prescription use and is not cleared for over-the-counter (OTC) use.

All facilities operated by LIFELINE FIRST AID LLC

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)

Cite this record

RegWarden. “LIFELINE FIRST AID LLC (FEI 3002714597) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3002714597-lifeline-first-aid-llc/

Not open yet

Alerts for LIFELINE FIRST AID LLC

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.